Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.
Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...
Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...